- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements ofCASI Pharmaceuticals, Inc.on Forms S-8 (File Nos. 333-68048, 333-188042, 333-101617 and 333-222043) and Forms S-3 (File Nos.333-80193, 333-84907, 333-76824, 333-104380, 333-110604, 333-122309, 333-133190, 333-132715, 333-151542, 333-167754, 333-182803, 333-200927, 333-214889, 333-222046, and 333-222701) of our report,dated March 29, 2018 onour audits of the consolidated financial statements ofCASI Pharmaceuticals, Inc., as of December 31, 2017 and 2016 and for the years then ended, included in this Annual Report on Form 10-K of CASI Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ CohnReznick LLP | |
Roseland, New Jersey | |
March 29, 2018 |